September 4, 2025.
Inke at CPHI Southeast Asia 2025
Last week, Inke participated in CPHI Southeast Asia 2025, a key regional event for the pharmaceutical industry that brought together stakeholders from across the ASEAN region. The event offered valuable insights into one of the world’s most dynamic and rapidly growing pharmaceutical markets.
During the exhibition, our team had the opportunity to connect with local and international partners, explore new business opportunities, and gain a deeper understanding of the evolving regulatory and market landscape in Southeast Asia.
Key Takeaways from the ASEAN Pharma Sector
-
Strong market for branded and imported generics: Branded products and imported generics continue to dominate in many ASEAN countries, particularly in the OINDP (orally inhaled and nasal drug products) segment.
-
Government support for local manufacturers: National authorities are actively encouraging local FDF (finished dosage form) manufacturers to build domestic capabilities and strengthen regional competitiveness.
-
Rising demand for inhalation therapies: With increasing awareness of COPD and other respiratory diseases, the need for inhalation therapies is expected to grow. Nasal sprays and classic pMDI formulations remain the most widely used OINDP products in the region.
-
Regulatory updates across ASEAN countries: New guidelines in Vietnam, Malaysia, and Thailand highlight the importance of regulatory alignment. A broader trend is emerging towards mutual recognition agreements within the ASEAN region for FDF approvals.
Inke’s Commitment to Southeast Asia
At Inke, we are proud to support our partners in Southeast Asia with:
-
High-quality inhalation APIs designed for respiratory and CNS applications.
-
Advanced micronisation technologies ensuring consistent particle size distribution and regulatory compliance.
-
More than 25 years of expertise in inhalation drug development and manufacturing.
By combining our technical know-how with a strong regulatory track record, Inke continues to be a trusted partner for companies across the ASEAN region.
We would like to thank all the stakeholders and partners we met in Kuala Lumpur for the insightful conversations and collaborative spirit. We look forward to building on these connections and continuing to contribute to the growth of the pharmaceutical industry in Southeast Asia.